Unravelling the cellular response to the SARS-COV-2 vaccine in inflammatory bowel disease patients on biologic drugs
Open Access
- 27 December 2023
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-11
Abstract
Suboptimal vaccine response is a significant concern in patients with Inflammatory Bowel Disease (IBD) receiving biologic drugs. This single-center observational study involved 754 patients with IBD. In Phase I (October 2020-April 2021), 754 IBD participants who had not previously received the SARS-CoV-2 vaccine, underwent blood extraction to assess the seroprevalence of SARS-CoV-2 infection and IBD-related factors. Phase II (May 2021-October 2021) included a subgroup of 52 IBD participants with confirmed previous SARS-CoV-2 infection, who were studied for humoral and cellular response to the SARS-CoV-2 vaccine. In Phase I, treatment with anti-TNF was associated with lower rates of seroconversion (aOR 0.25 95% CI [0.10–0.61]). In Phase II, a significant increase in post-vaccination IgG levels was observed regardless of biologic treatment. However, patients treated with anti-TNF exhibited significantly lower IgG levels compared to those without IBD therapy (5.32 ± 2.47 vs. 7.99 ± 2.59 U/ml, p = 0.042). Following vaccination, a lymphocyte, monocyte, and NK cell activation pattern was observed, with no significant differences between patients receiving biologic drugs and those without IBD treatment. Despite lower seroprevalence and humoral response to the SARS-CoV-2 vaccine in patients treated with anti-TNF, the cellular response to the vaccine did not differ significantly from that patients without IBD therapy.Keywords
Funding Information
- European Regional Development Fund (Group B29_17R)
- Centro de Investigación Biotecnológica en Red de Enfermedades Infecciosas (CB21/13/00087)
- Ministerio de Ciencia, Innovación y Universidades
- Agencia Estatal de Investigación (PID2020-113963RBI00)
- Fundación Inocente, Inocente
- Fundación Científica Asociación Española Contra el Cáncer
- ASPANOA
- Carrera de la mujer de Monzón
- Diputacion General de Aragon (DGACOVID-02)
This publication has 35 references indexed in Scilit:
- Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute Plasmodium falciparum Malaria: LAG-3 and TIM-3 Correlate With T Cell Activation and Course of DiseaseFrontiers in Immunology, 2020
- Are Patients with Inflammatory Bowel Disease at Increased Risk for Covid-19 Infection?Journal of Crohn's and Colitis, 2020
- Fecal bacteria from ulcerative colitis patients downregulate Tim-3-mediated inhibitory effects on monocytes in vitroMicrobial Pathogenesis, 2019
- Natural killer cell cytotoxicity and its regulation by inhibitory receptorsImmunology, 2018
- Analysis of PD-1 expression in the monocyte subsets from non-septic and septic preterm neonatesPLOS ONE, 2017
- Vaccinating Patients With Inflammatory Bowel Disease.2016
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune RegulationImmunity, 2016
- Activating KIRs and NKG2C in Viral Infections: Toward NK Cell Memory?Frontiers in Immunology, 2015
- Tim-3 regulates pro- and anti-inflammatory cytokine expression in human CD14+ monocytesJournal of Leukocyte Biology, 2011
- Changes to the Natural Killer Cell Repertoire after Therapeutic Hepatitis B DNA VaccinationPLOS ONE, 2010